Skye Bioscience, Inc. (SKYE) stock
SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.09+0.01 (+0.93%)
Close on Nov 13, 2026Market cap $4.82MP/E –Yield –
Earnings
Skye Bioscience's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q4 FY2025
–
EPS, Q4 FY2025
-$0.36
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Skye Bioscience's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2025ended Dec 31, 2025 | Mar 10, 2026after the close | – | – | -$0.36 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 10, 2025after the close | – | – | -$0.32 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | – | – | -$0.44 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | – | – | -$0.28 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 20, 2025after the close | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Skye Bioscience has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Skye Bioscience puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Skye Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Update
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- News
- Update
- Update
See a number that looks wrong?